<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Breast cellulitis and other skin disorders of the breast</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Breast cellulitis and other skin disorders of the breast</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Breast cellulitis and other skin disorders of the breast</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Michael Dixon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Larry M Baddour, MD, FIDSA, FAHA</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Sexton, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sandra Nelson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 23, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Breast cellulitis is a skin infection that occurs as a result of bacterial entry via breaches in the skin barrier. Issues related to breast cellulitis and other skin disorders of the breast will be reviewed here. Issues related to breast abscess and lactational mastitis are discussed separately, as are issues related to breast reconstruction. (See  <a class="medical medical_review" href="/d/html/795.html" rel="external">"Primary breast abscess"</a> and  <a class="medical medical_review" href="/d/html/798.html" rel="external">"Lactational mastitis"</a> and  <a class="medical medical_review" href="/d/html/801.html" rel="external">"Overview of breast reconstruction"</a>.)</p><p class="headingAnchor" id="H7390833"><span class="h1">ACUTE BREAST CELLULITIS</span></p><p class="headingAnchor" id="H3786583"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>Breast cellulitis is relatively uncommon. A prospective study including 3762 patients evaluated in a dedicated breast center during a 14-month interval found that 0.6 percent presented with erythema of the breast and, of those 22 patients, only 2 had cellulitis [<a href="#rid1">1</a>]. Among patients managed for breast cancer with breast-conserving surgery and radiation therapy, breast cellulitis occurs in 1 to 8 percent of patients [<a href="#rid2">2-7</a>].</p><p>Risk factors for breast cellulitis include [<a href="#rid1">1-5,7-10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prior breast cellulitis or infection</p><p class="bulletIndent1"><span class="glyph">●</span>Breast surgery within previous 30 days (surgical site infection)</p><p class="bulletIndent1"><span class="glyph">●</span>Lactation</p><p class="bulletIndent1"><span class="glyph">●</span>Trauma (eg, bites, nipple piercing, tattoos)</p><p class="bulletIndent1"><span class="glyph">●</span>Lesions in breast skin (eg, eczema, intertrigo, dermatitis, epidermolysis bullosa)</p><p></p><p>Issues related to delayed cellulitis following breast conservation therapy are discussed below. (See <a class="local">'Delayed cellulitis after breast conservation therapy'</a> below.)</p><p class="headingAnchor" id="H7047054"><span class="h2">Microbiology</span><span class="headingEndMark"> — </span>Beta-hemolytic streptococci are common causes of breast cellulitis [<a href="#rid3">3,9,11</a>]. Group B beta-hemolytic streptococci have a proclivity to produce soft tissue infections in the setting of venous and/or lymphatic compromise [<a href="#rid12">12</a>]; in one case-control study, for example, breast cancer was identified as a risk factor associated with the development of group B beta-hemolytic streptococcal infection [<a href="#rid13">13</a>].</p><p><em>Staphylococcus aureus</em>, including methicillin-resistant <em>S. aureus</em> (MRSA), can also be an important pathogen.</p><p class="headingAnchor" id="H12681954"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Clinical manifestation of breast cellulitis include pain, diffuse erythema, tenderness, and warmth [<a href="#rid2">2,4,5,8,14,15</a>]. Pain can occur before onset of erythema. Systemic symptoms, such as fever or chills, are uncommon, occurring in only 6 of 50 cases in one series [<a href="#rid4">4</a>]. The physical examination of the breast demonstrates localized or diffuse erythema, edema, marked tenderness, and warmth. Axillary nodes can be enlarged and tender. Spread of infection along lymphatic pathways (lymphangitis) can also be seen  (<a class="graphic graphic_picture graphicRef120786" href="/d/graphic/120786.html" rel="external">picture 1</a>).</p><p class="headingAnchor" id="H22190971"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of breast cellulitis is based on clinical manifestations [<a href="#rid6">6,16-21</a>]. The evaluation includes obtaining a clinical history to assess for trauma, underlying skin condition, breastfeeding, and previous breast surgery, breast cancer diagnosis, and/or local radiation treatment. A breast examination should be performed to assess the extent of erythema and swelling as well as for presence of tender and/or enlarged axillary lymph nodes.</p><p>No laboratory testing is diagnostic. Blood cultures are warranted in patients with rapidly progressive local changes of infection and/or evidence of systemic infection that includes hemodynamic instability, fever, chills, or malaise; otherwise, blood cultures are not necessary.</p><p>Radiographic imaging is useful if there is clinical suspicion of an underlying fluid collection, abscess, malignancy, or if there is no clinical improvement within 48 hours of appropriate antibiotic treatment. Ultrasound may demonstrate skin and subcutaneous edema; mammography may demonstrate mild skin thickening [<a href="#rid22">22</a>]. Magnetic resonance imaging (MRI) may demonstrate skin thickening and separation or septation of subcutaneous adipose tissue [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H1302185195"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Breast cellulitis must be distinguished from other inflammatory processes of the breast. Disruption of cutaneous lymphatics and/or circulation in the absence of an infectious process, such as a malignancy or an inflammatory process, can lead to a diffuse pattern of erythema that mimics cellulitis [<a href="#rid24">24-26</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Breast abscess – A breast abscess is a localized collection of pus in the breast tissue. Patients with breast abscess present with localized painful inflammation of the breast associated with fever and malaise, along with a fluctuant, tender, palpable mass. The diagnosis is based on clinical manifestations and ultrasonography. (See  <a class="medical medical_review" href="/d/html/795.html" rel="external">"Primary breast abscess"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin abscess overlying the breast – Skin abscesses involving the skin overlying the breast are usually related to an infected epidermoid cyst or related to hidradenitis suppurativa. (See <a class="local">'Epidermoid cyst'</a> below and <a class="local">'Hidradenitis suppurativa'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammatory breast cancer – Inflammatory breast cancer (IBC) should be considered if infection does not resolve with antimicrobial treatment. IBC may be distinguished by clinical manifestations of skin thickening due to edema, erythema, and peau d'orange appearance  (<a class="graphic graphic_picture graphicRef65383" href="/d/graphic/65383.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef70894" href="/d/graphic/70894.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef82220" href="/d/graphic/82220.html" rel="external">picture 4</a>). It is often associated with axillary lymphadenopathy. The diagnosis is established via biopsy. (See  <a class="medical medical_review" href="/d/html/768.html" rel="external">"Inflammatory breast cancer: Clinical features and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other breast malignancy – Comedo ductal carcinoma in situ can become infected and present with inflammation or an abscess [<a href="#rid27">27</a>]. In addition, advanced breast cancer can present with skin ulceration, malodorous necrosis, and secondary infection. These diagnoses are established via biopsy. (See  <a class="medical medical_review" href="/d/html/808.html" rel="external">"Diagnostic evaluation of suspected breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Paget disease of the breast – Paget disease of the breast (PDB) is a scaly, raw, vesicular, or ulcerated lesion that begins on the nipple and can spread to the areola  (<a class="graphic graphic_picture graphicRef60575" href="/d/graphic/60575.html" rel="external">picture 5</a>). The diagnosis is established by biopsy; the pathologic hallmark is the presence of malignant intraepithelial adenocarcinoma cells (Paget cells) within the epidermis of the nipple. Most cases are associated with an underlying invasive or noninvasive breast cancer. (See  <a class="medical medical_review" href="/d/html/814.html" rel="external">"Paget disease of the breast (PDB)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Superficial thrombophlebitis of the breast – Superficial thrombophlebitis of the breast, also known as Mondor disease, is a self-limiting disease involving the superficial veins of the breast and anterior chest wall  (<a class="graphic graphic_picture graphicRef64826" href="/d/graphic/64826.html" rel="external">picture 6</a>) [<a href="#rid28">28</a>]. Clinical manifestations include a thickened, tender cord with pain, erythema, and swelling; the syndrome can occur following surgery, core biopsy of the breast, radiation treatment, trauma, or unrelated to any antecedent event [<a href="#rid29">29-34</a>]. The condition usually resolves in four to six weeks with symptomatic treatment using analgesics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Morphea – Morphea (localized scleroderma) is an idiopathic inflammatory skin disorder associated with fibrosis  (<a class="graphic graphic_picture graphicRef73769" href="/d/graphic/73769.html" rel="external">picture 7</a>). It may be associated with radiation therapy  (<a class="graphic graphic_picture graphicRef120787" href="/d/graphic/120787.html" rel="external">picture 8</a>), trauma, breast implants, or autoimmune disease [<a href="#rid35">35</a>]. The initial sign of morphea is often abrupt onset of an erythematous patch or edematous plaque. Some patients may note pain or itching at the site prior to the development of a clinically evident lesion. Clinical manifestations include inflammation with hyperpigmentation, retraction, skin thickening, and fibrosis extending into the subcutaneous adipose tissue [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/13776.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative dermal lymphedema – Postoperative dermal lymphedema presents with cutaneous erythema and induration in the absence of tenderness, fever, or leukocytosis [<a href="#rid3">3,29,37</a>]. The breast involvement may be localized or diffuse. Lymphedema is a manifestation of lymphatic obstruction, which can occur following surgery alone or in conjunction with radiation treatment for breast cancer [<a href="#rid38">38,39</a>]. Clinical evaluation and surveillance are adequate; a biopsy should be performed if malignancy is suspected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation-induced dermatitis – Clinical manifestations of radiation-induced dermatitis include erythema, edema, pigment changes, epilation, and dry or moist desquamation  (<a class="graphic graphic_picture graphicRef120788" href="/d/graphic/120788.html" rel="external">picture 9</a>). These findings are strictly confined to the irradiated region and are not associated with fever or leukocytosis [<a href="#rid29">29</a>]. The diagnosis is established based on clinical manifestations. (See  <a class="medical medical_review" href="/d/html/13668.html" rel="external">"Radiation dermatitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Issues related to delayed cellulitis after breast conservation therapy are discussed below. (See <a class="local">'Delayed cellulitis after breast conservation therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation-induced fibrosis – Radiation-induced fibrosis can develop as a late effect of radiation treatment. Clinical manifestations include induration, thickening, and lymphedema in the skin and subcutaneous tissue of the breast. The diagnosis is established based on clinical manifestations. (See  <a class="medical medical_review" href="/d/html/7055.html" rel="external">"Clinical manifestations, prevention, and treatment of radiation-induced fibrosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spontaneous gangrene of the breast – Spontaneous gangrene of the breast with secondary infection can occur [<a href="#rid16">16</a>]. This is very rare; risk factors include diabetes and renal failure  (<a class="graphic graphic_picture graphicRef80652" href="/d/graphic/80652.html" rel="external">picture 10</a>). Spontaneous gangrene of the breast has also been reported in some patients within the first few days of receiving large doses of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>  (<a class="graphic graphic_picture graphicRef68120" href="/d/graphic/68120.html" rel="external">picture 11</a>) [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Skin necrosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bite wound – Clinical manifestations of bite wound infections may include tenderness, erythema, swelling, purulent drainage, lymphangitis, and fever. Management of human bites includes wound care, antibiotic therapy, and tetanus vaccination. (See  <a class="medical medical_review" href="/d/html/7674.html" rel="external">"Human bites: Evaluation and management", section on 'Management'</a>.)</p><p></p><p class="headingAnchor" id="H1315688"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Treatment of breast cellulitis includes antibiotics, symptomatic relief, and management of underlying predisposing conditions. </p><p class="headingAnchor" id="H456297668"><span class="h3">General measures</span><span class="headingEndMark"> — </span>To reduce local pain and swelling, we suggest nonsteroidal anti-inflammatory agents (eg, <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a>) along with cold compresses. </p><p>Skin conditions that predispose to the development of cellulitis, such as eczema or intertrigo (see <a class="local">'Skin disorders of the breast'</a> below), should be optimally managed. Diagnosis and treatment of such conditions are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a> and  <a class="medical medical_review" href="/d/html/115366.html" rel="external">"Intertrigo"</a>.)</p><p class="headingAnchor" id="H1657184741"><span class="h3">Antibiotic therapy</span><span class="headingEndMark"> — </span>Selection of antibiotic therapy is based on the suspected bacterial etiology as well as the patient’s severity of illness and underlying medical conditions. In general, the approach to antibiotic choice for acute breast cellulitis is the same as for cellulitis located elsewhere on the body, with the exception of dosing adjustments in certain cases. (See  <a class="medical medical_review" href="/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment", section on 'Selecting an antibiotic regimen'</a>.)</p><p>Certain soft tissue infections of the breast have distinct microbiology and specific treatment approaches. Treatment of such infections is discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>Cellulitis in the setting of breast implants (see  <a class="medical medical_review" href="/d/html/5536.html" rel="external">"Breast implant infections"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breast abscess (see  <a class="medical medical_review" href="/d/html/795.html" rel="external">"Primary breast abscess"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mastitis, including lactation-associated mastitis (see  <a class="medical medical_review" href="/d/html/794.html" rel="external">"Nonlactational mastitis in adults"</a> and  <a class="medical medical_review" href="/d/html/798.html" rel="external">"Lactational mastitis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cellulitis following localized trauma such as human bites, tattoos, or piercing (see  <a class="medical medical_review" href="/d/html/7674.html" rel="external">"Human bites: Evaluation and management"</a> and  <a class="medical medical_review" href="/d/html/15721.html" rel="external">"Tattooing in adolescents and young adults"</a> and  <a class="medical medical_review" href="/d/html/109.html" rel="external">"Body piercing in adolescents and young adults"</a>)</p><p></p><p class="headingAnchor" id="H1680004312"><span class="h4">Indications for parenteral therapy</span><span class="headingEndMark"> — </span>Most patients have uncomplicated infection that can be treated with oral antibiotics. However, some individuals warrant initial therapy with parenteral antibiotics.</p><p>We suggest initial parenteral therapy for individuals with the following clinical features:</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic symptoms (eg, fever &gt;100.5°F/38°C, hypotension, or sustained tachycardia)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid progression of erythema (eg, doubling the affected area within 24 hours; in particular, expansion over a few hours with severe pain should prompt consideration of a necrotizing infection) (see  <a class="medical medical_review" href="/d/html/7662.html" rel="external">"Necrotizing soft tissue infections", section on 'Typical findings'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extensive erythema or edema (eg, involving &gt;50 percent of the breast)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompromised state </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inability to absorb oral antibiotics</p><p></p><p class="headingAnchor" id="H2641062587"><span class="h4">Initial parenteral regimens</span><span class="headingEndMark"> — </span>When parenteral therapy is indicated, it should be started promptly. If possible, blood cultures should be obtained prior to initiation of parenteral antibiotics. Regimen selection is based on the likely microbiology and depends on the immune status of the patient. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompetent patients without sepsis and without MRSA risk factors</strong> — Most patients do not need empiric MRSA coverage, and antibiotics directed against streptococci and methicillin-sensitive <em>S. aureus </em>are effective. We suggest one of the following regimens:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">Cefazolin</a> 1 to 2 g intravenously every 8 hours</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">Nafcillin</a> 1 to 2 g intravenously every 4 hours<strong> </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9724" href="/d/drug information/9724.html" rel="external">Oxacillin</a> 1 to 2 g intravenously every 4 hours</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Flucloxacillin 2 g intravenously every 6 hours (not available in the United States)</p><p></p><p class="bulletIndent1">Although many patients have reported beta-lactam allergies, most do not have allergies that would prohibit the use of beta-lactams. In particular, many with penicillin allergies can still take a cephalosporin with or without a test dose. Evaluation of antibiotic allergies is particularly important for patients with breast cellulitis because they are at risk of subsequent infections (of the breast and elsewhere). Discussion of evaluation and management of reported penicillin allergies is presented in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients"</a> and  <a class="medical medical_review" href="/d/html/2087.html" rel="external">"Allergy evaluation for immediate penicillin allergy: Skin test-based diagnostic strategies and cross-reactivity with other beta-lactam antibiotics"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with serious beta-lactam allergies that preclude use of the above regimens, intravenous <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef128911" href="/d/graphic/128911.html" rel="external">table 1</a>) is an alternative. <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">Clindamycin</a> (600 to 900 mg intravenously every 8 hours) is another alternative, but risk of resistance or <em>C. difficile </em>may limit its utility. Local rates of streptococcal and staphylococcal resistance to clindamycin should be considered before prescribing. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompetent patients with sepsis or MRSA risk factors</strong> – Coverage of MRSA in addition to streptococci should be included when patients have sepsis or risk factors for MRSA, such as prior MRSA colonization or recent exposure to health care settings  (<a class="graphic graphic_table graphicRef53504" href="/d/graphic/53504.html" rel="external">table 2</a>). For such patients, we suggest the following: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> (see table for dosing  (<a class="graphic graphic_table graphicRef128911" href="/d/graphic/128911.html" rel="external">table 1</a>)) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompromised patients </strong>– These patients should receive antimicrobials with broadened activity that includes coverage against aerobic Gram-negative bacilli, including <em>Pseudomonas aeruginosa</em>. Additionally, we suggest empiric coverage with an agent active against MRSA. Example regimens include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> 15 to 20 mg/kg every 8 to 12 hours  (<a class="graphic graphic_table graphicRef128911" href="/d/graphic/128911.html" rel="external">table 1</a>)</p><p></p><p class="bulletIndent2"><strong>PLUS</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">Ceftazidime</a> (2 g every 8 hours) or <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> (2 g every 8 hours)</p><p></p><p class="bulletIndent1">Other agents that cover <em>P. aeruginosa</em> are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Intravenous antibiotics'</a>.)</p><p></p><p>When close follow-up is available, use of outpatient parenteral antimicrobial therapy (OPAT) may be favored due to its numerous benefits, including avoiding hospitalization. With this approach, patients are often seen initially in the hospital setting and are subsequently discharged on OPAT. Sometimes patients are transitioned directly to OPAT from an emergency department or clinic, although arranging OPAT from an outpatient setting can be logistically challenging. OPAT is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/d/html/117307.html" rel="external">"Outpatient parenteral antimicrobial therapy"</a>.)</p><p class="bulletIndent1">Once there is evidence of clinical improvement, regardless of whether a patient is being treated in the hospital setting or at home receiving OPAT, parenteral antibiotics should be switched to oral antibiotics with comparable antimicrobial coverage. (See <a class="local">'Initial oral regimens'</a> below.)</p><p></p><p class="headingAnchor" id="H730275472"><span class="h4">Initial oral regimens</span><span class="headingEndMark"> — </span>Most patients with breast cellulitis can be managed successfully with oral antibiotics in the outpatient setting. We recommend one of the following agents:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9349" href="/d/drug information/9349.html" rel="external">Dicloxacillin</a> 500 mg orally every 6 hours</p><p class="bulletIndent1"><span class="glyph">●</span>Flucloxacillin 500 to 1000 mg every 6 hours (not available in the United States)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9231" href="/d/drug information/9231.html" rel="external">Cephalexin</a> 500 mg orally every 6 hours </p><p></p><p>Certain situations warrant an alternative or adjusted oral regimen:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with breast edema or prior radiation therapy who do not meet criteria for parenteral antibiotics</strong> – Because these patients may have diminished local drug penetration, we increase the dose of <a class="drug drug_general" data-topicid="9349" href="/d/drug information/9349.html" rel="external">dicloxacillin</a> or <a class="drug drug_general" data-topicid="9231" href="/d/drug information/9231.html" rel="external">cephalexin</a> to 1000 mg orally every 6 hours for the first 48 hours, after which we reduce the dose to 500 mg orally every 6 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with beta-lactam allergy</strong> – We suggest <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> (300 mg to 450 orally every 8 hours).</p><p></p><p class="bulletIndent1">Because <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> is associated with elevated risk of <em>C. difficile </em>infection and antimicrobial resistance, careful evaluation of beta-lactam allergies should occur before choosing clindamycin. Most patients with reported beta-lactam allergies do not have allergies that would prohibit the use of beta-lactams. Evaluation of antibiotic allergies is particularly important for patients with breast cellulitis because they are at risk of subsequent infections (of the breast and elsewhere). Discussion of evaluation and management of reported penicillin allergies is presented in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2087.html" rel="external">"Allergy evaluation for immediate penicillin allergy: Skin test-based diagnostic strategies and cross-reactivity with other beta-lactam antibiotics"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with a history of MRSA or other MRSA risk factors</strong>  (<a class="graphic graphic_table graphicRef53504" href="/d/graphic/53504.html" rel="external">table 2</a>) – We suggest <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (one double-strength tablet orally twice daily), or the combination of <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> (875 mg orally twice daily) plus <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily). In general, <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> (450 mg orally every 8 hours) is an acceptable alternative, although we avoid using clindamycin due to risk for <em>C. difficile</em> infection and the possibility of streptococcal and staphylococcal resistance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompromised patients</strong> – For immunocompromised patients, we include coverage for both MRSA and <em>Pseudomonas </em>by adding <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> 500 to 750 mg orally twice daily to one of the oral regimens for immunocompetent patients with MRSA risk factors. </p><p></p><p class="headingAnchor" id="H1860229691"><span class="h3">Monitoring response to therapy</span><span class="headingEndMark"> — </span>Upon clinical presentation, we suggest outlining the area of cellulitis with a marker to help follow the clinical response to treatment  (<a class="graphic graphic_picture graphicRef120789" href="/d/graphic/120789.html" rel="external">picture 12</a>). Often, patients report improvement in pain before there is a noticeable decrease in erythema and edema. Clinical improvement should occur within 48 to 72 hours of treatment initiation. Absence of clinical response within this timeframe should prompt imaging (eg, ultrasound) to assess for abscess, re-evaluation of antibiotic coverage (including changing oral to parenteral therapy), and treatment of underlying predisposing conditions. Alternative diagnoses, such as necrotizing soft tissue infection or inflammatory breast cancer, should also be considered. (See  <a class="medical medical_review" href="/d/html/7662.html" rel="external">"Necrotizing soft tissue infections"</a> and  <a class="medical medical_review" href="/d/html/768.html" rel="external">"Inflammatory breast cancer: Clinical features and treatment"</a>.)</p><p class="headingAnchor" id="H199132431"><span class="h3">Duration of therapy</span><span class="headingEndMark"> — </span>The optimal duration of antibiotic therapy is uncertain. In general, antibiotics are continued until clinical signs of infection have resolved which usually takes 5 to 14 days. Longer durations may be warranted for patients with breast cellulitis after breast-conserving surgery or prior radiation therapy. </p><p class="headingAnchor" id="H2248529175"><span class="h3">Recurrence of infection</span></p><p class="headingAnchor" id="H3939761011"><span class="h4">Management of recurrent infection</span><span class="headingEndMark"> — </span>In general, the same approach and antibiotic regimens are used for recurrences as for initial episodes. If available, microbiologic data from prior episodes should guide antibiotic management for recurrences. (See <a class="local">'Antibiotic therapy'</a> above.)</p><p class="headingAnchor" id="H3066981947"><span class="h4">Prevention of recurrent infection</span><span class="headingEndMark"> — </span>Interventions to prevent recurrent infections include management of underlying predisposing conditions and prophylactic antibiotic therapy.</p><p>The presence of edema can limit the response to antibiotic therapy and can be challenging to treat. Although compression therapy is helpful for edematous cellulitis of the extremities, compression of breast edema is usually not feasible. Chronic skin conditions that predispose to cellulitis should be treated, with input from dermatologic specialists if necessary. We advise patients to keep the skin as clean and dry as possible by washing the area in a shower or bath and then patting the area dry with a cotton towel; if necessary, using a hair dryer (on a low or no-heat setting to prevent burn injury) may help with drying. For individuals with recurrence of proven <em>S. aureus</em> cellulitis, attempting decolonization is reasonable. (See  <a class="medical medical_review" href="/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control", section on 'Targeted decolonization'</a>.)</p><p>The role of prophylactic antibiotics for prevention of recurrent breast cellulitis is unclear. Management of these patients should be done in concert with infectious disease specialists or others with relevant expertise. Some studies suggest benefit for patients with recurrent cellulitis, but these studies did not include patients with breast cellulitis. Prophylactic antibiotics for cellulitis are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment", section on 'Prevention of recurrences'</a>.) </p><p class="headingAnchor" id="H2863309579"><span class="h1">DELAYED CELLULITIS AFTER BREAST CONSERVATION THERAPY</span></p><p class="headingAnchor" id="H2066450110"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>Following breast conservation treatment for breast cancer (breast conserving surgery and radiation therapy), cellulitis may occur months to years later. </p><p>Risk factors include [<a href="#rid5">5,41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Obesity</p><p class="bulletIndent1"><span class="glyph">●</span>Hematoma formation</p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative bruising</p><p class="bulletIndent1"><span class="glyph">●</span>Breast edema</p><p class="bulletIndent1"><span class="glyph">●</span>Large resected volume</p><p class="bulletIndent1"><span class="glyph">●</span>Need for multiple seroma aspiration</p><p class="bulletIndent1"><span class="glyph">●</span>Connective tissue disorders</p><p></p><p class="headingAnchor" id="H3924970859"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Delayed breast cellulitis may reflect an inflammatory process; bacteria may contribute to its development and to the chances of recurrence [<a href="#rid41">41</a>]. The microbiology of delayed breast cellulitis is the same as that of acute breast cellulitis. (See <a class="local">'Microbiology'</a> above.)</p><p class="headingAnchor" id="H4161941328"><span class="h2">Clinical manifestations and diagnosis</span><span class="headingEndMark"> — </span>Delayed breast cellulitis typically occurs within a few months following completion of radiotherapy. In most women, erythema subsides within a year, but breast edema can remain long term. </p><p>Clinical manifestations of delayed breast cellulitis are similar to those of acute cellulitis  (<a class="graphic graphic_picture graphicRef120785" href="/d/graphic/120785.html" rel="external">picture 13</a>). Pain tends to be greatest at the end of the day and least in the morning. (See <a class="local">'Clinical manifestations'</a> above.)</p><p>It can be a challenge to differentiate delayed breast cellulitis from postoperative infection, radiation cellulitis, and recurrent inflammatory carcinoma. (See <a class="local">'Differential diagnosis'</a> above.)</p><p class="headingAnchor" id="H2686769130"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The optimal approach to treatment of delayed breast cellulitis is uncertain. Some have suggested that delayed breast cellulitis may be noninfectious in origin and that anti-inflammatory therapy may be sufficient [<a href="#rid41">41</a>]; however, such patients typically present with systemic manifestations (fever, chills) and often respond to antibiotic therapy with activity against beta-hemolytic streptococci and <em>S. aureus</em> [<a href="#rid3">3</a>]. (See <a class="local">'Antibiotic therapy'</a> above.)</p><p>Improving lymphatic stasis and its consequences by manual lymphatic drainage, massage, and skin care may help improve this condition. </p><p>If the erythema and edema persist, a punch or core biopsy should be performed to exclude recurrent breast cancer. </p><p class="headingAnchor" id="H7390364"><span class="h1">SKIN DISORDERS OF THE BREAST</span><span class="headingEndMark"> — </span>Some skin disorders of the breast may be associated with cellulitis [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H7390384"><span class="h2">Eczema</span><span class="headingEndMark"> — </span>Eczema is characterized by thickened skin, increased skin markings (lichenification), and excoriated and fibrotic papules. The diagnosis is established based on clinical manifestations. Patients with eczema involving the skin overlying the breast may develop secondary cellulitis  (<a class="graphic graphic_picture graphicRef50819" href="/d/graphic/50819.html" rel="external">picture 14</a>). (See  <a class="medical medical_review" href="/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H7390419"><span class="h2">Epidermoid cyst</span><span class="headingEndMark"> — </span>An epidermoid cyst is a discrete, freely movable nodule. The diagnosis of an epidermoid cyst is based upon clinical appearance and palpation. These cysts are common within the skin of the breast and can become secondarily infected  (<a class="graphic graphic_picture graphicRef66484" href="/d/graphic/66484.html" rel="external">picture 15</a>). (See  <a class="medical medical_review" href="/d/html/5573.html" rel="external">"Overview of benign lesions of the skin", section on 'Epidermoid cyst'</a>.)</p><p class="headingAnchor" id="H7390454"><span class="h2">Hidradenitis suppurativa</span><span class="headingEndMark"> — </span>Hidradenitis suppurativa is a chronic inflammatory condition of the apocrine sweat glands; it can be associated with infection and abscess formation of the axilla or skin of the lower half of the breast  (<a class="graphic graphic_picture graphicRef64307" href="/d/graphic/64307.html" rel="external">picture 16</a>) [<a href="#rid16">16,27,43-46</a>]. Lesions frequently contain both aerobic and anaerobic bacteria. (See  <a class="medical medical_review" href="/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H7390603"><span class="h2">Intertrigo</span><span class="headingEndMark"> — </span>Intertrigo refers to inflammation at the site of two closely opposed skin surfaces (intertriginous area), often due to moisture and maceration  (<a class="graphic graphic_picture graphicRef65405" href="/d/graphic/65405.html" rel="external">picture 17</a>) [<a href="#rid47">47,48</a>]. The diagnosis is based on clinical manifestations. Intertrigo can be a recurrent problem in women with large ptotic breasts that make contact with the chest wall, usually affecting the skin of the lower half of the breast. </p><p class="headingAnchor" id="H7390664"><span class="h2">Pilonidal sinus</span><span class="headingEndMark"> — </span>A pilonidal sinus is a cavity in the skin with a narrow opening on the surface that contains hair and skin debris. Pilonidal sinuses affecting the nipple have been described in hairdressers and sheep shearers and occur as a result of small pieces of cut hair that accumulate in clothing and penetrate the skin, causing inflammation and infection [<a href="#rid16">16,44,49-52</a>].</p><p class="headingAnchor" id="H7390784"><span class="h2">Piercing</span><span class="headingEndMark"> — </span>Nipple rings can cause subareolar breast abscess and recurrent nipple infections, particularly in smokers  (<a class="graphic graphic_picture graphicRef63150" href="/d/graphic/63150.html" rel="external">picture 18</a>) [<a href="#rid53">53</a>]. In a study of 68 patients with a primary breast abscess, nipple piercing was a risk factor for a subareolar breast abscess (odds ratio [OR] 20, 95% CI 2.01-204.28) in addition to smoking (OR 11, 95% CI 4.41-29.94). (See  <a class="medical medical_review" href="/d/html/109.html" rel="external">"Body piercing in adolescents and young adults", section on 'Localized infection'</a>.)</p><p class="headingAnchor" id="H4100958680"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/121714.html" rel="external">"Society guideline links: Evaluation of breast problems"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation </strong>–<strong> </strong>Patients with acute breast cellulitis present with a tender, warm, erythematous, and edematous breast. Pain often precedes other symptoms. Clinical presentation can overlap with multiple other breast conditions that should be considered at the time of diagnosis. (See <a class="local">'Clinical manifestations'</a> above and <a class="local">'Differential diagnosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> –<strong> </strong>Most cases of breast cellulitis are caused by beta-hemolytic streptococci or <em>Staphylococcus aureus</em>, including methicillin-resistant <em>S. aureus </em>(MRSA). (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>–<strong> </strong>Patients with acute breast cellulitis are treated with antibiotics, symptomatic relief, and management of underlying conditions (eg, eczema). (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for parenteral therapy </strong>–<strong> </strong>Similar to the general approach to cellulitis, for patients with signs of systemic toxicity, extensive disease, or rapidly progressive erythema, we collect blood cultures then treat with parenteral antibiotics. Otherwise, oral antibiotics are usually sufficient. (See <a class="local">'Indications for parenteral therapy'</a> above and  <a class="medical medical_review" href="/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment", section on 'Indications for parenteral therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Regimen selection</strong>: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Immunocompetent patients without sepsis and without MRSA risk factors</strong>  (<a class="graphic graphic_table graphicRef53504" href="/d/graphic/53504.html" rel="external">table 2</a>) –<strong> </strong>Parenteral options include <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a> 1 to 2 g intravenously every 8 hours or <a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">nafcillin</a> 1 to 2 g intravenously every 4 hours. Oral options include <a class="drug drug_general" data-topicid="9349" href="/d/drug information/9349.html" rel="external">dicloxacillin</a> 500 mg orally every 6 hours or <a class="drug drug_general" data-topicid="9231" href="/d/drug information/9231.html" rel="external">cephalexin</a> 500 mg orally every 6 hours. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Immunocompetent patients with sepsis or MRSA risk factors</strong>  (<a class="graphic graphic_table graphicRef53504" href="/d/graphic/53504.html" rel="external">table 2</a>) –<strong> </strong>Parenteral options include intravenous <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef128911" href="/d/graphic/128911.html" rel="external">table 1</a>). Oral options for patients with MRSA risk factors who are not septic include <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (one double-strength tablet orally twice daily), the combination of <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> (875 mg orally twice daily) plus <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily), or <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> (450 mg orally every 8 hours).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Immunocompromised patients </strong>–<strong> </strong>We use broader antimicrobial therapy for these individuals given their elevated risk of atypical pathogens and rapid progression. Parenteral options include the combination of intravenous <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef128911" href="/d/graphic/128911.html" rel="external">table 1</a>) plus <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> 2 g every 8 hours. For oral therapy, we add <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (500 to 750 mg orally twice daily) to the oral regimens for immunocompetent patients with MRSA risk factors.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients with beta-lactam allergy </strong>–<strong> </strong>Many patients with reported beta-lactam allergies do not have allergies that prohibit the use of beta-lactams. In particular, many with penicillin allergies can still take a cephalosporin with or without a test dose. Careful evaluation to confirm the presence of serious beta-lactam allergies should occur before selecting alternative agents. Parenteral options include intravenous <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef128911" href="/d/graphic/128911.html" rel="external">table 1</a>) or <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> 600 to 900 mg intravenously every 8 hours. Oral options include clindamycin 300 to 450 mg orally every 8 hours. (See  <a class="medical medical_review" href="/d/html/2087.html" rel="external">"Allergy evaluation for immediate penicillin allergy: Skin test-based diagnostic strategies and cross-reactivity with other beta-lactam antibiotics"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of antimicrobial therapy </strong>–<strong> </strong>The duration of therapy is usually 5 to 14 days, depending on response to treatment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring response to therapy </strong>–<strong> </strong>Absence of clinical response to antibiotic therapy within 48 to 72 hours should prompt ultrasound to assess for abscess, re-evaluation of antibiotic choices, treatment of underlying predisposing conditions, and consideration of alternative diagnoses such as necrotizing soft tissue infection or inflammatory breast cancer. (See <a class="local">'Monitoring response to therapy'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Froman J, Landercasper J, Ellis R, et al. Red breast as a presenting complaint at a breast center: an institutional review. Surgery 2011; 149:813.</a></li><li><a class="nounderline abstract_t">Hughes LL, Styblo TM, Thoms WW, et al. Cellulitis of the breast as a complication of breast-conserving surgery and irradiation. Am J Clin Oncol 1997; 20:338.</a></li><li><a class="nounderline abstract_t">Mertz KR, Baddour LM, Bell JL, Gwin JL. Breast cellulitis following breast conservation therapy: a novel complication of medical progress. Clin Infect Dis 1998; 26:481.</a></li><li><a class="nounderline abstract_t">Indelicato DJ, Grobmyer SR, Newlin H, et al. Delayed breast cellulitis: an evolving complication of breast conservation. Int J Radiat Oncol Biol Phys 2006; 66:1339.</a></li><li><a class="nounderline abstract_t">Brewer VH, Hahn KA, Rohrbach BW, et al. Risk factor analysis for breast cellulitis complicating breast conservation therapy. Clin Infect Dis 2000; 31:654.</a></li><li><a class="nounderline abstract_t">Zippel D, Siegelmann-Danieli N, Ayalon S, et al. Delayed breast cellulitis following breast conserving operation. Eur J Surg Oncol 2003; 29:327.</a></li><li><a class="nounderline abstract_t">Baddour LM. Breast cellulitis complicating breast conservation therapy. J Intern Med 1999; 245:5.</a></li><li><a class="nounderline abstract_t">Miller SR, Mondry T, Reed JS, et al. Delayed cellulitis associated with conservative therapy for breast cancer. J Surg Oncol 1998; 67:242.</a></li><li><a class="nounderline abstract_t">Rescigno J, McCormick B, Brown AE, Myskowski PL. Breast cellulitis after conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 1994; 29:163.</a></li><li><a class="nounderline abstract_t">Alderden J, Pepper GA, Wilson A, et al. Predicting Pressure Injury in Critical Care Patients: A Machine-Learning Model. Am J Crit Care 2018; 27:461.</a></li><li><a class="nounderline abstract_t">Simon MS, Cody RL. Cellulitis after axillary lymph node dissection for carcinoma of the breast. Am J Med 1992; 93:543.</a></li><li><a class="nounderline abstract_t">Baddour LM, Bisno AL. Non-group A beta-hemolytic streptococcal cellulitis. Association with venous and lymphatic compromise. Am J Med 1985; 79:155.</a></li><li><a class="nounderline abstract_t">Jackson LA, Hilsdon R, Farley MM, et al. Risk factors for group B streptococcal disease in adults. Ann Intern Med 1995; 123:415.</a></li><li><a class="nounderline abstract_t">Peltecu G. Images in clinical medicine. Cellulitis after treatment for breast cancer. N Engl J Med 2007; 357:488.</a></li><li><a class="nounderline abstract_t">Staren ED, Klepac S, Smith AP, et al. The dilemma of delayed cellulitis after breast conservation therapy. Arch Surg 1996; 131:651.</a></li><li class="breakAll">Dixon JM. Breast infection. In: ABC of Breast Diseases, Dixon JM (Ed), Blackwell Publishing, Oxford 2006. p.19.</li><li><a class="nounderline abstract_t">Foxman B, D'Arcy H, Gillespie B, et al. Lactation mastitis: occurrence and medical management among 946 breastfeeding women in the United States. Am J Epidemiol 2002; 155:103.</a></li><li><a class="nounderline abstract_t">Committee on Health Care for Underserved Women, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 361: Breastfeeding: maternal and infant aspects. Obstet Gynecol 2007; 109:479.</a></li><li><a class="nounderline abstract_t">Stafford I, Hernandez J, Laibl V, et al. Community-acquired methicillin-resistant Staphylococcus aureus among patients with puerperal mastitis requiring hospitalization. Obstet Gynecol 2008; 112:533.</a></li><li><a class="nounderline abstract_t">Jahanfar S, Ng CJ, Teng CL. Antibiotics for mastitis in breastfeeding women. Cochrane Database Syst Rev 2009; :CD005458.</a></li><li class="breakAll">Hale TW, Berens PD. Clinical Therapy in Breastfeeding Patients, 2nd ed, Pharmasoft, Amarillo 2002.</li><li><a class="nounderline abstract_t">Peters F, Petersen EE, Kirkpatrick CJ. Isolated erythema (cellulitis) of the breast. Breast 2002; 11:484.</a></li><li><a class="nounderline abstract_t">Rahmouni A, Chosidow O, Mathieu D, et al. MR imaging in acute infectious cellulitis. Radiology 1994; 192:493.</a></li><li><a class="nounderline abstract_t">Vitug AF, Newman LA. Complications in breast surgery. Surg Clin North Am 2007; 87:431.</a></li><li><a class="nounderline abstract_t">Throckmorton AD, Boughey JC, Boostrom SY, et al. Postoperative prophylactic antibiotics and surgical site infection rates in breast surgery patients. Ann Surg Oncol 2009; 16:2464.</a></li><li><a class="nounderline abstract_t">McNeely ML, Binkley JM, Pusic AL, et al. A prospective model of care for breast cancer rehabilitation: postoperative and postreconstructive issues. Cancer 2012; 118:2226.</a></li><li class="breakAll">Dixon JM, Bundred NJ. Management of disorders of the ductal system and infections. In: Diseases of the Breast, Harris JR, Lippman ME, Morrow M, Osborne CK (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. p.47.</li><li><a class="nounderline abstract_t">Becker L, McCurdy LI, Taves DH. Superficial thrombophlebitis of the breast (Mondor's disease). Can Assoc Radiol J 2001; 52:193.</a></li><li><a class="nounderline abstract_t">Milgrom S, Higgins SA. Management of cellulitis associated with treatment of breast cancer. J Support Oncol 2009; 7:174.</a></li><li><a class="nounderline abstract_t">Catania S, Zurrida S, Veronesi P, et al. Mondor's disease and breast cancer. Cancer 1992; 69:2267.</a></li><li><a class="nounderline abstract_t">Shetty MK, Watson AB. Mondor's disease of the breast: sonographic and mammographic findings. AJR Am J Roentgenol 2001; 177:893.</a></li><li><a class="nounderline abstract_t">Yanik B, Conkbayir I, Oner O, Hekimoğlu B. Imaging findings in Mondor's disease. J Clin Ultrasound 2003; 31:103.</a></li><li><a class="nounderline abstract_t">Pasta V, D'Orazi V, Sottile D, et al. Breast Mondor's disease: Diagnosis and management of six new cases of this underestimated pathology. Phlebology 2015; 30:564.</a></li><li><a class="nounderline abstract_t">Laroche JP, Galanaud J, Labau D, et al. Mondor's disease: what's new since 1939? Thromb Res 2012; 130 Suppl 1:S56.</a></li><li><a class="nounderline abstract_t">Clark CJ, Wechter D. Morphea of the breast--an uncommon cause of breast erythema. Am J Surg 2010; 200:173.</a></li><li><a class="nounderline abstract_t">Dubner S, Bovi J, White J, Susnik B. Postirradiation morphea in a breast cancer patient. Breast J 2006; 12:173.</a></li><li><a class="nounderline abstract_t">King R, Duncan L, Shupp DL, Googe PB. Postsurgical dermal lymphedema clinically mimicking inflammatory breast carcinoma. Arch Dermatol 2001; 137:969.</a></li><li><a class="nounderline abstract_t">Browse NL, Stewart G. Lymphoedema: pathophysiology and classification. J Cardiovasc Surg (Torino) 1985; 26:91.</a></li><li><a class="nounderline abstract_t">Marcks P. Lymphedema. Pathogenesis, prevention, and treatment. Cancer Pract 1997; 5:32.</a></li><li><a class="nounderline abstract_t">Bauer KA. Coumarin-induced skin necrosis. Arch Dermatol 1993; 129:766.</a></li><li><a class="nounderline abstract_t">Exarchos G, Metaxa L, Constantinidou A, Kontos M. Delayed Breast Cellulitis following Surgery for Breast Cancer: A Literature Review. Breast Care (Basel) 2019; 14:48.</a></li><li><a class="nounderline abstract_t">Dixon JM, Khan LR. Treatment of breast infection. BMJ 2011; 342:d396.</a></li><li><a class="nounderline abstract_t">Attar KH, Waghorn D, Lyons M, Cunnick G. Rare species of actinomyces as causative pathogens in breast abscess. Breast J 2007; 13:501.</a></li><li><a class="nounderline abstract_t">Dixon JM. Breast abscess. Br J Hosp Med (Lond) 2007; 68:315.</a></li><li><a class="nounderline abstract_t">Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60:539.</a></li><li><a class="nounderline abstract_t">Buimer MG, Wobbes T, Klinkenbijl JH. Hidradenitis suppurativa. Br J Surg 2009; 96:350.</a></li><li><a class="nounderline abstract_t">Janniger CK, Schwartz RA, Szepietowski JC, Reich A. Intertrigo and common secondary skin infections. Am Fam Physician 2005; 72:833.</a></li><li><a class="nounderline abstract_t">Mistiaen P, Poot E, Hickox S, et al. Preventing and treating intertrigo in the large skin folds of adults: a literature overview. Dermatol Nurs 2004; 16:43.</a></li><li><a class="nounderline abstract_t">Gannon MX, Crowson MC, Fielding JW. Periareolar pilonidal abscesses in a hairdresser. BMJ 1988; 297:1641.</a></li><li><a class="nounderline abstract_t">Banerjee A. Pilonidal sinus of nipple in a canine beautician. BMJ 1985; 291:1787.</a></li><li><a class="nounderline abstract_t">Bowers PW. Roustabouts' and barbers' breast. Clin Exp Dermatol 1982; 7:445.</a></li><li class="breakAll">Dixon JM. Benign breast disease. In: The New Airds Companion to Surgical Studies, Burnand KG, Young AE (Eds), Churchill Livingstone, Edinburgh 1992. p.811.</li><li><a class="nounderline abstract_t">Gollapalli V, Liao J, Dudakovic A, et al. Risk factors for development and recurrence of primary breast abscesses. J Am Coll Surg 2010; 211:41.</a></li></ol></div><div id="topicVersionRevision">Topic 797 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21397287" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Red breast as a presenting complaint at a breast center: an institutional review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9256885" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cellulitis of the breast as a complication of breast-conserving surgery and irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9502474" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Breast cellulitis following breast conservation therapy: a novel complication of medical progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17126205" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Delayed breast cellulitis: an evolving complication of breast conservation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017810" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk factor analysis for breast cellulitis complicating breast conservation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12711284" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Delayed breast cellulitis following breast conserving operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10095811" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Breast cellulitis complicating breast conservation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9579371" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Delayed cellulitis associated with conservative therapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8175424" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Breast cellulitis after conservative surgery and radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30385537" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Predicting Pressure Injury in Critical Care Patients: A Machine-Learning Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1364813" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cellulitis after axillary lymph node dissection for carcinoma of the breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3875287" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Non-group A beta-hemolytic streptococcal cellulitis. Association with venous and lymphatic compromise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7639440" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk factors for group B streptococcal disease in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671257" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Images in clinical medicine. Cellulitis after treatment for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8645074" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The dilemma of delayed cellulitis after breast conservation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8645074" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The dilemma of delayed cellulitis after breast conservation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11790672" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Lactation mastitis: occurrence and medical management among 946 breastfeeding women in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17267864" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : ACOG Committee Opinion No. 361: Breastfeeding: maternal and infant aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757649" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Community-acquired methicillin-resistant Staphylococcus aureus among patients with puerperal mastitis requiring hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160255" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Antibiotics for mastitis in breastfeeding women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160255" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antibiotics for mastitis in breastfeeding women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14965714" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Isolated erythema (cellulitis) of the breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8029421" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : MR imaging in acute infectious cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17498536" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Complications in breast surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19506959" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Postoperative prophylactic antibiotics and surgical site infection rates in breast surgery patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22488697" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A prospective model of care for breast cancer rehabilitation: postoperative and postreconstructive issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22488697" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A prospective model of care for breast cancer rehabilitation: postoperative and postreconstructive issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11436415" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Superficial thrombophlebitis of the breast (Mondor's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19831161" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Management of cellulitis associated with treatment of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1562972" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mondor's disease and breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11566698" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mondor's disease of the breast: sonographic and mammographic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12539252" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Imaging findings in Mondor's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25261462" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Breast Mondor's disease: Diagnosis and management of six new cases of this underestimated pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23026664" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mondor's disease: what's new since 1939?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20637350" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Morphea of the breast--an uncommon cause of breast erythema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16509846" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Postirradiation morphea in a breast cancer patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11453830" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Postsurgical dermal lymphedema clinically mimicking inflammatory breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3884629" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Lymphoedema: pathophysiology and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9128494" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Lymphedema. Pathogenesis, prevention, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8507082" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Coumarin-induced skin necrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31019443" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Delayed Breast Cellulitis following Surgery for Breast Cancer: A Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21317199" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Treatment of breast infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17760673" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Rare species of actinomyces as causative pathogens in breast abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17639835" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Breast abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19293006" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hidradenitis suppurativa: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19283748" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16156342" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Intertrigo and common secondary skin infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15022504" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Preventing and treating intertrigo in the large skin folds of adults: a literature overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3147779" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Periareolar pilonidal abscesses in a hairdresser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pilonidal sinus of nipple in a canine beautician</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6897026" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Roustabouts' and barbers' breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6897026" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Roustabouts' and barbers' breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610247" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Risk factors for development and recurrence of primary breast abscesses.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
